TD Asset Management Inc. lowered its position in shares of GlycoMimetics, Inc. (NASDAQ:GLYC) by 21.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 25,300 shares of the biotechnology company’s stock after selling 7,100 shares during the period. TD Asset Management Inc. owned 0.08% of GlycoMimetics worth $354,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Fox Run Management L.L.C. acquired a new stake in GlycoMimetics during the third quarter worth approximately $173,000. Dynamic Technology Lab Private Ltd acquired a new stake in GlycoMimetics during the second quarter worth approximately $146,000. Citadel Advisors LLC acquired a new stake in GlycoMimetics during the second quarter worth approximately $249,000. Russell Investments Group Ltd. grew its position in GlycoMimetics by 172.4% during the second quarter. Russell Investments Group Ltd. now owns 31,379 shares of the biotechnology company’s stock worth $350,000 after buying an additional 19,859 shares in the last quarter. Finally, Virtu KCG Holdings LLC acquired a new stake in GlycoMimetics during the second quarter worth approximately $569,000. 86.81% of the stock is currently owned by institutional investors and hedge funds.

GLYC has been the topic of a number of analyst reports. ValuEngine raised GlycoMimetics from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. SunTrust Banks reissued a “buy” rating and set a $21.00 price target on shares of GlycoMimetics in a research report on Wednesday, October 4th. Zacks Investment Research raised GlycoMimetics from a “hold” rating to a “buy” rating and set a $15.00 price target on the stock in a research report on Friday, October 6th. Roth Capital initiated coverage on GlycoMimetics in a research report on Monday, October 23rd. They set a “buy” rating and a $25.00 price target on the stock. Finally, Jefferies Group reissued a “buy” rating and set a $16.00 price target on shares of GlycoMimetics in a research report on Thursday, October 26th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $20.17.

In other GlycoMimetics news, SVP Helen M. Thackray sold 2,000 shares of the firm’s stock in a transaction on Monday, September 18th. The stock was sold at an average price of $13.00, for a total value of $26,000.00. Following the sale, the senior vice president now owns 150,615 shares of the company’s stock, valued at approximately $1,957,995. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 43.80% of the company’s stock.

Shares of GlycoMimetics, Inc. (GLYC) opened at $16.51 on Friday. GlycoMimetics, Inc. has a twelve month low of $3.82 and a twelve month high of $18.25.

GlycoMimetics (NASDAQ:GLYC) last issued its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.24) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.04. research analysts forecast that GlycoMimetics, Inc. will post -1.12 EPS for the current fiscal year.

WARNING: “TD Asset Management Inc. Sells 7,100 Shares of GlycoMimetics, Inc. (GLYC)” was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.watchlistnews.com/td-asset-management-inc-sells-7100-shares-of-glycomimetics-inc-glyc/1767364.html.

GlycoMimetics Profile

GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.

Want to see what other hedge funds are holding GLYC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlycoMimetics, Inc. (NASDAQ:GLYC).

Institutional Ownership by Quarter for GlycoMimetics (NASDAQ:GLYC)

Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with Analyst Ratings Network's FREE daily email newsletter.